ReviewCancer2011
Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis.
Review in Cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03825289 (THREAD), which is not on this map. Cited by 76 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
THREAD: A Phase I Trial of Trametinib and Hydroxychloroquine in Patients With Advanced Pancreatic Cancer
Who cites it
76 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Pharmacoeconomic evaluation of direct oral anticoagulants for cancer-associated thrombosis: a systematic review.Frontiers in public health · 2025Pooled it
- American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer.Blood advances · 2021Guideline
- Epidemiology of Cancer-Associated Thrombosis in Asia: A Systematic Review.Frontiers in cardiovascular medicine · 2021Pooled it
- Guidelines for Perioperative Care for Pancreatoduodenectomy: Enhanced Recovery After Surgery (ERAS) Recommendations 2019.World journal of surgery · 2020Pooled it
- Trial
- Burden of cardiovascular disease in Japanese cancer patients and survivors: a single cancer-center study in Niigata City.International journal of clinical oncology · 2019Trial
- Development and validation of a nomogram for predicting venous thromboembolism risk in colorectal cancer patients undergoing postoperative chemotherapy.Medical oncology (Northwood, London, England) · 2026Article
- Extended anticoagulation with DOACs in patients affected by hematologic malignancies and venous thromboembolism: a monocentric experience.Journal of thrombosis and thrombolysis · 2026Article
- Practical considerations about management of pulmonary embolism in patients with cancer.Journal of thrombosis and thrombolysis · 2026Review
- Factors Associated and Survival Outcomes Among Japanese Patients with Solid Cancer Who Developed Deep Vein Thrombosis (DVT).International journal of general medicine · 2026Article
- Avatrombopag switching from other thrombopoietic agents in severe and persistent cancer treatment-induced thrombocytopenia: a multicentre real-world study.Frontiers in medicine · 2026Article
- Comparative safety and effectiveness of apixaban and rivaroxaban for treatment of cancer-associated venous thromboembolism: A retrospective cohort study.PLoS medicine · 2025Article
- Article
- Evaluation of acute thrombus regression effect of edoxaban for deep vein thrombosis in patients with cancer: a single-center prospective observational study.Heart and vessels · 2024Observational
- Cardiovascular disease burden in patients with urological cancers: The new discipline of uro-cardio-oncology.Cancer innovation · 2024Review
- Article
- A Comprehensive Review of Risk Factors and Thrombophilia Evaluation in Venous Thromboembolism.Journal of clinical medicine · 2024Review
- A New Risk Prediction Model for Venous Thromboembolism and Death in Ambulatory Lung Cancer Patients.Cancers · 2023Article
- The Risk of Venous Thromboembolism in Korean Patients with Breast Cancer: A Single-Center Experience.Cancers · 2023Article
- Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Venous thromboembolism (VTE) is a significant cause of morbidity and mortality in patients with cancer. The risk of VTE varies over the natural history of cancer, with the highest risk occurring during hospitalization and after disease recurrence. Patient and disease characteristics are associated with further increased risk of VTE in this setting. Specific factors include cancer type (eg, pancreatic cancer, brain cancer, lymphoma) and the presence of metastatic disease at the time of diagnosis. VTE is a significant predictor of increased mortality during the first year among all types and stages of cancer, with metastatic disease reported to be the strongest predictor of mortality. VTE is also associated with early death in ambulatory patients with cancer. These data highlight the need for close monitoring, prompt treatment, and appropriate preventive strategies for VTE in patients with cancer. The American Society of Clinical Oncology and the National Comprehensive Cancer Network have issued guidelines regarding the prophylaxis and treatment of patients with cancer. This review summarizes the impact of VTE on patients with cancer, the effects of VTE on clinical outcomes, the importance of thromboprophylaxis in this population, relevant ongoing clinical trials examining the prevention of VTE, and new pharmacologic treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.